Monday, November 26, 2018

Godrej Properties rises 2% as Deutsche Bank sees 49% upside

Deutsche said the impact of joint venture with Hero Cycles on near-term financials would be limited.


Godrej Properties shares gained 2.5 percent intraday Tuesday as global investment firm Deutsche Bank remained bullish on the stock. It is in addition to 3 percent rally seen in previous session.
The research firm has a buy call on the Mumbai-based real estate developer with a target price at Rs 1,000, implying a massive 49 percent potential upside.
Deutsche said the impact of joint venture with Hero Cycles on near-term financials would be limited.
On Monday, Godrej Fund Management, the real estate private equity arm of the Godrej Group, and Godrej Properties entered into a joint venture with Hero Cycles for their Golf Course Road property in Gurgaon.
The joint venture will develop, lease, and manage around 1 million square feet of prime office and retail space on the 4-acre property.
At 11:27 hours IST, the stock was quoting at Rs 680.10, up Rs 8.75, or 1.30 percent on the BSE
GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

Bargain hunting: SBI, Indian Hotels among top 10 buys for 1-2 years horizon

The upcoming results of state elections in December and general elections in 2019 will give enough entry points for investors as markets are likely to remain volatile, suggest experts



While S&P BSE Sensex is down about 10 percent from the highs it hit in August, many small, mid and large-cap stocks have corrected way more than that in just a matter of months.

There are local and global triggers that led to the sudden fall in markets. On the macro front, the rise in crude oil prices as well as fall in rupee weighed on investor sentiment.
However, investors can use the opportunity to build their portfolio by buying into quality stocks with an investment horizon of 1-2 years, suggest experts.
The September quarter results were a mixed bag failed to lift investor sentiment. The upcoming results of state elections in December and general elections in 2019 will give enough entry points for investors as markets are likely to remain volatile, suggest experts.
“We have a preference for largecaps post the correction in valuations, with continued volatility and with important events (state elections) ahead, we see opportunities emerging in the mid-cap space also,” Gaurav Dua, Head of Research, Sharekhan by BNP Paribas told Moneycontrol.
“Improvement in the macro environment does have a positive impact on equities. Easing of crude oil prices, stability in rupee and its possible fallout on monetary policy has aided sentiment. Along with domestic macro factors, the sentiment in the Indian equity market has also been aided by the recent rally across emerging markets due to signs of peaking out of the continuous strengthening of the US Dollar,” he said.
On the sectoral front, Pankaj Pandey, Head-Research, ICICIdirect.com told Moneycontrol that he is positive on pharma (stabilised US, strong growth in India, improved margins), corporate banks (peaked out NPA cycle, asset resolution), IT (strong deal pipeline & valuation comfort) and capital goods (strong order inflows, improved working capital cycle).
ICICI Lombard General Insurance is the country's leading private sector general insurance company with a market share of 16.8 percent in that space. Overall, it is the fourth-largest player and held a market share of 8.2 percent as of March.
Few regulatory factors such as increasing FDI limit to 49 percent from 26 percent and mandatory cover of third-party motor insurance to three years for four-wheelers and to five years for two-wheelers bodes well for the industry.
In addition, the Company is investing heavily in emerging technologies such as artificial intelligence, automation, and machine learning to remove human intervention in the distribution of products and service claims, which helped the Company increase its market share in travel insurance to 24.9 percent in FY 2018 from 20.8 percent in FY 2017.
In the engineering segment, it went up to 11.2 percent from 9.8 percent, while fire insurance rose to 8.5 percent from 7.5 percent. The marine insurance increased to 12.7 percent from 11.7 percent.

GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

Sun Pharma shares erase initial gains, slide 6%

Polo Pharma, acquired by Sun Pharma, has a portfolio of dermatology products.



Shares of Sun Pharmaceutical Industries erased initial gains, plunging about 6 percent after a settlement with certain plaintiffs in the Modafinil Antitrust Litigation matter pending in a US district court.

The company did not disclose the settlement amount.
The stock had risen as much as 2 percent in early trade after the acquisition of Japanese pharmaceutical company Polo Pharma for $1 million.
Polo Pharma has a portfolio of dermatology products and has two manufacturing facilities at Saitama.
"This acquisition is in line with our strategy to strengthen our global dermatology presence," Kirti Ganorkar, Executive Vice President, Sun Pharma said in a statement.
At 11:32 hours Sun Pharma was quoting at Rs 484.25 on the BSE, down 5.17 percent from the previous close.

GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

IIFL Holdings gains 2% as subsidiary to acquire 15% stake in fin-tech startup

Trendlyne is a stock market analytics platform for retail investors, analysts, fund managers and advisors.


IIFL Holdings shares gained 1.88 percent in morning on Tuesday after its subsidiary decided to acquire around 15 percent stake in fin-tech startup.
"Subsidiary IIFL Securities is in the process of acquiring 15 percent strategic stake in Bangalore-based fin-tech startup Trendlyne (Giskard Datatech Private Ltd)," the company said in its filing.
Trendlyne is a stock market analytics platform for retail investors, analysts, fund managers and advisors.
IIFL Securities, the securities trading and financial products distribution firm, has 3.7 percent share of daily cash turnover in Indian markets and its mobile app IIFL Markets has over 2.1 million users.
Founded by Amber Pabreja and Devi Yesodharan, Trendlyne.com simplifies investing via its cloud-based, proprietary always-on data-engine strategies that processes hundreds of millions of rows of data to give powerful insights in real-time.
"Trendlyne offers retail investors access to advanced analytical tools – screeners, deep analytics, powering features like complex querying, backtesting, DVM scores, custom alerts and superstar portfolio," Aniruddha Dange, Digital Strategy Head, IIFL Group said.
At 09:44 hours IST, the stock was quoting at Rs 483.95, up Rs 7.00, or 1.47 percent on the BSE.

GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS


IFCI surges 6% as co receives Rs 492 cr for Binani Cement resolution

On account of resolution of Binani Cement through NCLT, IFCI received an amount of Rs 491.84 crore.



Shares of IFCI gained 6.5 percent intraday Tuesday after company received Rs 492 crore under the resolution plan for Binani Cement under the IBC mechanism.
"On account of resolution of Binani Cement through NCLT, IFCI, which is holding 42,16,850 security receipts of the face value of Rs 1,000 each has received an amount of Rs 491.84 crore, net of TDS of Rs 30.55 crore, pursuant to the said resolution, as per company release.
On November 14, Aditya Birla Group firm UltraTech Cement won bid to acquire debt-ridden Binani Cement after the National Company Law Appellate Tribunal (NCLAT) approved its revised Rs 7,950.34 crore bid over an offer by rival Dalmia Bharat Group.
In approving UltraTech's resolution plan for Binani, which was auctioned to recover unpaid bank dues, NCLAT may have set a precedence as it favoured a proposal that not just paid the financial lenders but also operational creditors.
At 09:50 hrs IFCI was quoting at Rs 14.41, up Rs 0.70, or 5.11 percent on the BSE.
The share touched its 52-week high Rs 34.55 and 52-week low Rs 11.50 on 15 January, 2018 and 08 October, 2018, respectively.
Currently, it is trading 58.12 percent below its 52-week high and 25.83 percent above its 52-week low.

GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

Friday, November 23, 2018

Glenmark Pharma gains 2% on USFDA approval for antimicrobial drug

Atovaquone is a generic version of Mepron oral suspension, 750 mg/5 mL, of GlaxoSmithKline LLC.




Glenmark Pharmaceuticals shares gained 1.7 percent in morning on Thursday after the US health regulator approved antimicrobial drug of the company.
"The United States Food & Drug Administration (USFDA) granted final approval for Atovaquone oral suspension, which is available in 750 mg/5 mL strength," the company said in its filing.
Abbreviated new drug application was filed by its US subsidiary.
Atovaquone is a generic version of Mepron oral suspension, 750 mg/5 mL, of GlaxoSmithKline LLC.
According to IQVIATM sales data, the Mepron market achieved annual sales of approximately $119.1 million.
Glenmark's current portfolio consists of 144 products authorized for distribution in the US marketplace and 55 ANDA's pending approval with the US FDA.
At 09:50 hours IST, the stock was quoting at Rs 643.85, up Rs 2.65, or 0.41 percent on the BSE.

GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS


Investec raises HDFC target as co should benefit from the liquidity crisis

Investec expects HDFC to grow at 16 percent compounded annual growth rate (CAGR) over the medium-term.





Housing Development Finance Corporation shares gained a percent in morning on Thursday as Investec believes company should benefit from the liquidity crisis on account of its strengths on liability side.
While having a buy call on the stock, the research house raised its target price to Rs 1,950 from Rs 1,825 earlier, implying a 4 percent potential upside.
Investec expects HDFC to gain market share in the current year, preserving its profitability, and expects more than 14 percent value compounding over medium-term.
The research house also expects the housing finance company to grow at 16 percent compounded annual growth rate (CAGR) over the medium-term.
IL&FS-led debt crisis in September not only hit non-banking finance companies but also housing finance companies, which resulted into sharp fall in stock prices of these companies.
Most analysts believe this crisis is expected benefit to banks as well as big companies which can able to manage funding, but small NBFCs & HFCs may find it difficult.
At 10:55 hours IST, the stock was quoting at Rs 1,883.25, up Rs 15.35, or 0.82 percent on the BSE.
GET TWO DAYS FREE TRIAL>>>>COMMODITY TIPS

Suven Life Sciences gains 3% on product patents in Brazil and Eurasia

These two patents are valid through 2023 and 2034 respectively. Suven Life Sciences shares gained 2.7 percent in morning on Thursd...